Frances Levin
Kennedy-Leavy Professor of Psychiatry and Chief of the Division on Substance Use Disorders at Columbia University / New York State Psychiatric Institute
Data updated
Research Footprint
Frances Levin appears in 5 tracked papers (2014–2020), most studied alongside Ketamine and Placebo, across Substance Use Disorders (SUD), Depressive Disorders and Safety & Risk Management.
Most-cited paper: A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial (176 citations).
Frequent co-authors: Elias Dakwar, Edward Nunes and Carl Hart.
Background & Research
Frances Rudnick Levin, MD is a psychiatrist and addiction researcher at Columbia University and the New York State Psychiatric Institute. Her work has focused on pharmacologic and psychotherapeutic treatments for substance use disorders, especially cocaine, alcohol, and co-occurring psychiatric conditions. She has published extensively on ketamine-assisted interventions and other treatments for addiction.
Key Impact
A leading addiction psychiatrist whose ketamine and psychotherapy studies helped establish ketamine as a promising treatment approach for cocaine and alcohol use disorders.
Collaboration Network
4 collaborators· click a node to visit their profile
Full network →Affiliations
Institutions, companies, and organisations Frances Levin is associated with.
Columbia University
academicResearch with psychedelics has been taking place at Columbia University in New York since 2014. Researchers from various departments at the university including Medicine, Psychology and Psychiatry have conducted numerous trials investigating the effects ketamine has on substance use disorders. Some research exploring the anti-depressant effects of ketamine has also taken place. More recently, Columbia University served as a test site for COMPASS Pathway's COMP360 trial which explored the effects of psilocybin on treatment-resistant depression. Professor of Clinical Psychiatry, Dr David Hellerstein served as the principal investigator at this study site.
View stakeholder →CUIMC
Columbia University Irving Medical Center (CUIMC) is a major academic medical centre in New York City, integrating Columbia University's Vagelos College of Physicians and Surgeons with NewYork-Presbyterian Hospital and conducting research across neuroscience, psychiatry, and translational medicine. CUIMC serves as the primary clinical site for the Ketamine Biomarker Validation trial (NCT07307768), an EEG-based Phase I study examining dose-response relationships across three ketamine infusion levels in adults with treatment-resistant major depressive disorder.
View stakeholder →New York State Psychiatric Institute
State-funded psychiatric research institute affiliated with Columbia University, located in New York City. A key site for psilocybin clinical trials including the landmark COMP360 study for treatment-resistant depression, and conducts broader research on LSD, DMT, ayahuasca, and ketamine through Columbia's Depression Evaluation Service.
View stakeholder →National Institute on Drug Abuse (NIDA)
governmentU.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
View stakeholder →